---
title: "CRO concept stocks opened lower, SC Pharmaceuticals and Sinobioway Medicine hit the daily limit down"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/237744997.md"
description: "CRO concept stocks opened lower, SC Pharmaceuticals and Sinobioway Medicine hit the daily limit down, while Boji Pharmaceutical, Hongbo Pharmaceutical, and Haofan Biotechnology all opened lower"
datetime: "2025-04-28T01:30:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/237744997.md)
  - [en](https://longbridge.com/en/news/237744997.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/237744997.md)
generator: "portal-rs"
---

# CRO concept stocks opened lower, SC Pharmaceuticals and Sinobioway Medicine hit the daily limit down

CRO concept stocks opened lower, SC Pharmaceuticals and Sinobioway Medicine hit the daily limit down, while Boji Pharmaceutical, Hongbo Pharmaceutical, and Haofan Biotechnology all opened lower

### Related Stocks

- [002581.CN](https://longbridge.com/en/quote/002581.CN.md)
- [002693.CN](https://longbridge.com/en/quote/002693.CN.md)
- [301393.CN](https://longbridge.com/en/quote/301393.CN.md)
- [300404.CN](https://longbridge.com/en/quote/300404.CN.md)
- [301230.CN](https://longbridge.com/en/quote/301230.CN.md)

## Related News & Research

- [Livzon Pharma buys 3.5% Xinbeijiang Pharma stake for RMB 106.7 million](https://longbridge.com/en/news/296601614.md)
- [Gen X Parents Thought They'd Be Preparing for Retirement by Now. Instead, They're Still Paying Their Adult Kids' Bills](https://longbridge.com/en/news/296512321.md)
- [OncoZenge registers 772,797 shares in directed issue after SEK 5 million payment from Sichuan Yangtian](https://longbridge.com/en/news/296607308.md)
- [giga! Equips All Eligible MILK Fund Scholars with One-year gigaFLEX+ Plan](https://longbridge.com/en/news/296587727.md)
- [CSPC Innovation Pharmaceutical: Biopharma licensing and product launches drove record revenue and profit growth](https://longbridge.com/en/news/296129143.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**